Nanomaterials for Fluorescence and Multimodal Bioimaging

Chem Rec. 2023 Mar;23(3):e202200253. doi: 10.1002/tcr.202200253. Epub 2023 Feb 15.

Abstract

Bioconjugated nanomaterials replace molecular probes in bioanalysis and bioimaging in vitro and in vivo. Nanoparticles of silica, metals, semiconductors, polymers, and supramolecular systems, conjugated with contrast agents and drugs for image-guided (MRI, fluorescence, PET, Raman, SPECT, photodynamic, photothermal, and photoacoustic) therapy infiltrate into preclinical and clinical settings. Small bioactive molecules like peptides, proteins, or DNA conjugated to the surfaces of drugs or probes help us to interface them with cells and tissues. Nevertheless, the toxicity and pharmacokinetics of nanodrugs, nanoprobes, and their components become the clinical barriers, underscoring the significance of developing biocompatible next-generation drugs and contrast agents. This account provides state-of-the-art advancements in the preparation and biological applications of bioconjugated nanomaterials and their molecular, cell, and in vivo applications. It focuses on the preparation, bioimaging, and bioanalytical applications of monomodal and multimodal nanoprobes composed of quantum dots, quantum clusters, iron oxide nanoparticles, and a few rare earth metal ion complexes.

Keywords: Bioimaging; DNA; MRI; fluorescence; intracellular delivery; in vivo imaging; multimodality; quantum dots.

Publication types

  • Review

MeSH terms

  • Contrast Media
  • Fluorescence
  • Nanoparticles* / chemistry
  • Nanostructures* / chemistry
  • Quantum Dots*

Substances

  • Contrast Media

Grants and funding